Case and Research Letter
Omalizumab-Associated Steatohepatitis
Esteatohepatitis asociada a omalizumab
Read
2953
Timeswas read the article
1040
Total PDF
1913
Total HTML
Share statistics
array:24 [ "pii" => "S0001731022008286" "issn" => "00017310" "doi" => "10.1016/j.ad.2021.10.023" "estado" => "S300" "fechaPublicacion" => "2023-07-01" "aid" => "3227" "copyright" => "AEDV" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2023;114:650-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S0001731023004295" "issn" => "00017310" "doi" => "10.1016/j.ad.2021.10.029" "estado" => "S300" "fechaPublicacion" => "2023-07-01" "aid" => "3526" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2023;114:T650-T651" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Cartas científico-clínicas</span>" "titulo" => "Esteatohepatitis asociada a omalizumab" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "T650" "paginaFinal" => "T651" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Omalizumab-Associated Steatohepatitis" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Barbosa, M. Coelho, A. Brasileiro, A. Giménez-Arnau" "autores" => array:4 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Barbosa" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Coelho" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Brasileiro" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Giménez-Arnau" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004295?idApp=UINPBA000044" "url" => "/00017310/0000011400000007/v1_202307101051/S0001731023004295/v1_202307101051/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0001731023004313" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.06.003" "estado" => "S300" "fechaPublicacion" => "2023-07-01" "aid" => "3528" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2023;114:T649" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Images in Dermatology</span>" "titulo" => " Extranodal Natural Killer/T-cell Lymphoma Mimicking Ringworm" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "T649" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Linfoma extranodal de células Natural Killer/T imitando una tiña" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 584 "Ancho" => 901 "Tamanyo" => 98158 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Casanova-Esquembre, J. Lorca Spröngle, A. Pérez-Ferriols" "autores" => array:3 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Casanova-Esquembre" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Lorca Spröngle" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Pérez-Ferriols" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004313?idApp=UINPBA000044" "url" => "/00017310/0000011400000007/v1_202307101051/S0001731023004313/v1_202307101051/en/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S0001731023004295" "issn" => "00017310" "doi" => "10.1016/j.ad.2021.10.029" "estado" => "S300" "fechaPublicacion" => "2023-07-01" "aid" => "3526" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2023;114:T650-T651" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Cartas científico-clínicas</span>" "titulo" => "Esteatohepatitis asociada a omalizumab" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "T650" "paginaFinal" => "T651" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Omalizumab-Associated Steatohepatitis" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Barbosa, M. Coelho, A. Brasileiro, A. Giménez-Arnau" "autores" => array:4 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Barbosa" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Coelho" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Brasileiro" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Giménez-Arnau" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004295?idApp=UINPBA000044" "url" => "/00017310/0000011400000007/v1_202307101051/S0001731023004295/v1_202307101051/es/main.assets" ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>" "titulo" => "Omalizumab-Associated Steatohepatitis" "tieneTextoCompleto" => true "saludo" => "To the Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "650" "paginaFinal" => "651" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J. Barbosa, M. Coelho, A. Brasileiro, A. Giménez-Arnau" "autores" => array:4 [ 0 => array:4 [ "nombre" => "J." "apellidos" => "Barbosa" "email" => array:1 [ 0 => "joanafabarbosa@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "M." "apellidos" => "Coelho" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "A." "apellidos" => "Brasileiro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "A." "apellidos" => "Giménez-Arnau" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Dermatology and Venereology Department, Hospital de Santo António dos Capuchos, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Dermatology, Hospital del Mar, Institut Mar D’Investigacions Mediques, Universitat Autònoma, Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Esteatohepatitis asociada a omalizumab" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives, angioedema, or both, for a minimum of 6 weeks, without any known external trigger. The EAACI/GA<span class="elsevierStyleSup">2</span>LEN/EDF/WAO guidelines<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">1</span></a> recommend second-generation H1 antihistamines as the first-line treatment for CSU, with up to fourfold dose increase as required. If disease control is not achieved, add-on therapy with omalizumab is recommended. Other options such as cyclosporine A may also be considered, as well as short-course oral corticosteroids for exacerbations.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">1</span></a> Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">2</span></a> It is generally well tolerated. The most common adverse events include nasopharyngitis, sinusitis, upper respiratory tract infection, headache and cough.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">We report the case of a 40-year-old non-obese man diagnosed with severe CSU (Urticaria Activity Score 7 (UAS7)<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>30) with angioedema. He denied previous relevant medical history. Initial investigations including full blood count, liver enzymes, renal and thyroid function, erythrocyte sedimentation rate and total IgE were all within normal ranges, as well as negative viral hepatitis serology. He was previously treated with updosed non-sedating H1-antihistamines with poor response. Oral cyclosporine 5<span class="elsevierStyleHsp" style=""></span>mg/kg/day was added and symptom control was achieved (UAS7 0). However, due to rapid recurrence after dose-tapering and infectious adverse effects with higher doses, it was discontinued. Short courses of systemic corticosteroids were also required to relief the symptoms. Liver enzymes remained unchanged.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Omalizumab 300<span class="elsevierStyleHsp" style=""></span>mg by subcutaneous injection every four weeks was added to fourfold-H1 antihistamines. Complete remission of symptoms was achieved within two weeks. Three months later, the patient started complaining of postprandial fullness and abdominal pain. Laboratory workup revealed persistent elevation of liver enzymes (aspartate transaminase 35–61<span class="elsevierStyleHsp" style=""></span>U/L, alanine transaminase 79–157<span class="elsevierStyleHsp" style=""></span>U/L, gamma-GT 115–276<span class="elsevierStyleHsp" style=""></span>U/L), which were within the normal range at baseline. Lipid profile, viral hepatitis serology and autoimmune blood tests were unremarkable. Abdominal ultrasound and computed tomography showed no significant changes. A liver biopsy was performed and revealed low grade steatohepatitis, which in the absence of another plausible cause (dyslipidaemia, alcohol intake, viral infection, metabolic syndrome), was assumed to be most likely associated with omalizumab. The drug was discontinued and liver enzymes returned to normal ranges. However, the patient experienced worsening of the CSU, without satisfactory control with H1-antihistamines and cyclosporine (4<span class="elsevierStyleHsp" style=""></span>mg/kg/day). Due to the high impact on patient's quality of life, not only because of the associated pruritus, but also due to the fact that urticaria lesions were located in visible areas, the possibility of reintroducing omalizumab was considered and discussed with his hepatologist.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Given the lack of other available options for the treatment of CSU, the patient's desire to maintain therapy, the low degree of hepatic inflammation on liver biopsy, and the reticuloendothelial clearance of omalizumab making it unlikely to be altered by hepatic impairment,<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">2</span></a> it was decided to restart omalizumab administration with close analytical monitoring. Such therapeutic strategy has been followed in the last two years, maintaining moderate liver enzymes rise and CSU activity was completely controlled (UAS7 0).</p><p id="par0025" class="elsevierStylePara elsevierViewall">To the best of our knowledge, this is the first case report of steatohepatitis associated with omalizumab. Liver function impairment has not yet been described. Additionally, the effectiveness and safety of omalizumab has been reported in patients with CSU and hepatitis C and B.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">3,4</span></a> Considering that fact, as well as the safety data available and the mechanism of omalizumab metabolization, nothing would predict the hepatotoxicity of the drug. Our patient's symptoms triggered the investigation that revealed an unintended adverse effect. However, it has been possible to continue therapy with omalizumab without severe adverse effects. Such approach should always be considered on a case-by-case basis.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of interest</span><p id="par0030" class="elsevierStylePara elsevierViewall">Ana Brasileiro participated in educational activities for AbbVie, Janssen-Cilag, Leo-Pharma and Novartis.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Ana M. Giménez-Arnau: Medical Advisor for Uriach Pharma, Genentech, Novartis, FAES, GSK, Sanofi-Regeneron, Amgen, Thermo Fisher Scientific; Research Grants supported by Uriach Pharma, Novartis, Grants from Instituto Carlos III-FEDER; Educational activities for Uriach Pharma, Novartis, Genentech, Menarini, LEO-PHARMA, GSK, MSD, Almirall, Sanofi.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0025" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The EAACI/GA<span class="elsevierStyleSup">2</span>LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Zuberbier" 1 => "W. Aberer" 2 => "R. Asero" 3 => "A.H. Abdul Latiff" 4 => "D. Baker" 5 => "B. Ballmer-Weber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/all.13397" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2018" "volumen" => "73" "paginaInicial" => "1393" "paginaFinal" => "1414" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29336054" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0030" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.M. Giménez-Arnau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/14712598.2017.1285903" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Biol Ther" "fecha" => "2017" "volumen" => "17" "paginaInicial" => "375" "paginaFinal" => "385" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28125304" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0035" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Leiva-Salinas" 1 => "L. Francés" 2 => "I. Marin-Cabanas" 3 => "M.P. Arribas Granados" 4 => "J.F. Silvestre" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.12450" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2015" "volumen" => "29" "paginaInicial" => "1027" "paginaFinal" => "1028" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24629127" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0040" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of omalizumab in a patient with chronic spontaneous urticaria and active hepatitis B virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Chicharro" 1 => "P. Rodríguez-Jiménez" 2 => "D. de Argila" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2016.10.005" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2017" "volumen" => "108" "paginaInicial" => "383" "paginaFinal" => "384" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27914623" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/0000011400000007/v1_202307101051/S0001731022008286/v1_202307101051/en/main.assets" "Apartado" => array:4 [ "identificador" => "6160" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Cartas científico-clínicas" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000007/v1_202307101051/S0001731022008286/v1_202307101051/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731022008286?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 20 | 15 | 35 |
| 2024 October | 151 | 54 | 205 |
| 2024 September | 125 | 32 | 157 |
| 2024 August | 120 | 66 | 186 |
| 2024 July | 142 | 40 | 182 |
| 2024 June | 105 | 53 | 158 |
| 2024 May | 107 | 40 | 147 |
| 2024 April | 98 | 39 | 137 |
| 2024 March | 89 | 37 | 126 |
| 2024 February | 71 | 39 | 110 |
| 2024 January | 76 | 45 | 121 |
| 2023 December | 67 | 52 | 119 |
| 2023 November | 61 | 29 | 90 |
| 2023 October | 76 | 61 | 137 |
| 2023 September | 51 | 36 | 87 |
| 2023 August | 85 | 32 | 117 |
| 2023 July | 158 | 74 | 232 |
| 2023 June | 54 | 33 | 87 |
| 2023 May | 43 | 21 | 64 |
| 2023 April | 16 | 12 | 28 |
| 2023 March | 36 | 31 | 67 |
| 2023 February | 30 | 33 | 63 |
| 2023 January | 35 | 39 | 74 |
| 2022 December | 58 | 50 | 108 |
| 2022 November | 24 | 26 | 50 |
| 2022 October | 15 | 51 | 66 |
Show all
